[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100477569":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":33,"locations":38,"responsibleParty":56,"collaborators":10,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":10,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":10,"studyType":71,"phases":10,"briefSummary":72,"conditions":73,"keywords":77,"overallStatus":41,"whyStopped":10,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Beijing Friendship Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Sacubitril\u002Fvalsartan group",null,"Patients administered sacubitril \u002F valsartan oral tablet (Entresto) 200mg 1\u002Fday by prescription that have started before inclusion of the patient enrolled into the study and defined as sacubitril\u002Fvalsartan group.",[13],"Drug: Sacubitril \u002F Valsartan Oral Tablet [Entresto]",{"label":15,"type":10,"description":16,"interventionNames":17},"ACEI\u002FARB group","Patients administered angiotensin-converting enzyme inhibitors\u002Fangiotensin II receptor antagonists (ACEI\u002FARB) by prescription that have started before inclusion of the patient enrolled into the study and defined as ACEI\u002FARB group.\n\nIncluding:\n\nbenazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan.",[18],"Drug: ACEI\u002FARB",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"DRUG","Sacubitril \u002F Valsartan Oral Tablet [Entresto]","There is no treatment allocation. Patients administered sacubitril \u002F valsartan oral tablet (Entresto) 200mg 1\u002Fday by prescription that have started before inclusion of the patient enrolled into the study and defined as sacubitril\u002Fvalsartan group.",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"ACEI\u002FARB","There is no treatment allocation. Patients administered angiotensin-converting enzyme inhibitors\u002Fangiotensin II receptor antagonists (ACEI\u002FARB) by prescription that have started before inclusion of the patient enrolled into the study and defined as ACEI\u002FARB group.\n\nIncluding:\n\nbenazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan.",[15],[30],{"name":31,"affiliation":5,"role":32},"Rongchong Huang, M.D.","PRINCIPAL_INVESTIGATOR",[34],{"name":31,"role":35,"phone":36,"phoneExt":10,"email":37},"CONTACT","+86-13811039417","rchuang@ccmu.edu.cn",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Beijing Friendship Hospital, Capital Medical University","RECRUITING","Beijing","Beijing Municipality","100050","China","CN",{"type":48,"coordinates":49},"Point",[50,51],116.39723,39.9075,{"lat":51,"lon":50},[54,55],{"name":31,"role":35,"phone":36,"phoneExt":10,"email":37},{"name":31,"role":32,"phone":10,"phoneExt":10,"email":10},{"type":57,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100477569","effect-of-sacubitrilvalsartan-on-cardiac-function-in-hypertensive-patients-stratified-by-bmi-a-real-world-study-100477569",false,"NCT05498675","Effect of Sacubitril\u002FValsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study","Effect of Sacubitril\u002FValsartan on Cardiac Function Assessed by Cardiac Magnetic Resonance (CMR) in Hypertensive Patients Stratified by Body Mass Index (BMI): A Real World Study","Inclusion Criteria:\n\n* Patients with essential hypertension\n* 18-70 years old\n* No major barriers to provide written consent\n\nExclusion Criteria:\n\n* Secondary hypertension, except because of sleep apnea\n* cardiovascular disease (myocardial infarction, heart failure, stroke or coronary revascularization) within 6 months\n* Severe concomitant diseases (autoimmune disease, malignancy, late stage of liver diseases, respiratory diseases and digestive diseases)\n* Unable to understand or comply with the study procedures","ALL","18 Years","70 Years",{"count":69,"type":70},180,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to investigate the effect of sacubitril\u002Fvalsartan on cardiac function assessed by cardiac magnetic resonance (CMR) in hypertensive patients stratified by BMI.",[74,75,76],"Sacubitril\u002FValsartan","Hypertension","Obesity",[78,79],"Cardiac function","Cardiac magnetic resonance","2025-02-11",{"date":82,"type":83},"2025-02-13","ACTUAL",{"date":85,"type":83},"2021-09-01",{"date":87,"type":70},"2027-06-30",{"name":5,"class":6},1]